Loading stock…

3SBio Inc. (1530) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

3SBio Inc.

1530Market cap $4.99BPrice $1.9

Country🇨🇳China

SectorHealthcare

IndustryBiotechnology

3SBio develops and manufactures biopharmaceutical drugs treating cancer, kidney disease, and autoimmune disorders across China. It's one of the country's few biotech firms with a fully integrated pipeline from R&D through commercial production, serving millions of patients nationwide.

In Bastion Portfolios?

52W Return-47%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+36%10

Revenue Forecast

Rev CAGR (1y)-45%1

Rev CAGR (3y)-15%1

Rev CAGR (5y)+7%6

Earnings Forecast

EPS Growth Y+1-71%1

EPS Growth Y+2+26%8

EPS Growth Y+3+19%8

Quality

Margins

EBIT Margin60%10

Net Income Margin46%10

Free Cash Flow Margin51%10

Debt

Net Debt/EBITDA-1.410

Efficiency

ROE38%10

ROA30%10

Earnings Stability77

GEAR+STRONG81

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)137

P/E Ratio (Forward 3y)98

P/BV1.29

EV Multiples

EV/EBITDA Fwd59

EV/EBIT Fwd610

Yield

Free Cash Flow Yield27.0%10

Dividend Yieldna–

Momentum

Short term

1 month return-5%5

3 month return-10%3

YTD return-34%1

Mid term

Price vs 52wHigh43%1

1 year return-49%1

Long term

3 year return+155%9

5 year return+137%8

Risk Shield

Price Risk

Beta0.95

Volatility59%2

Free Cash Flow

Free Cash Flow Margin51%10

Free Cash Flow Yield27.0%10

Quality

ROCE42%10

Earnings Stability77

Net Debt/EBITDA-1.410

02Growth

Is it actually growing, and how fast?

15303SBio

Revenue FY25$2.5B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+36%10

Revenue, next 1Y-45%1

Revenue, next 3Y, CAGR-15%1

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-71%1

EPS growth, FY27E+26%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 36%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

Earnings are set to grow faster than sales (EPS about 19%/yr vs revenue -15%/yr), so margins should widen. One year dips: EPS falls 71% next year.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to shrink 15%/yr over the next 3 years, behind most of the market.3/10

Revenue grew 36%/yr over the last 3 years, but it is set to shrink 15%/yr from here.

BOTTOM LINE

Steady Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

15303SBio

Total return Current108%

Price return Current97.0%

MOMENTUM RATING↗

WEAK28 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-10%3

YTD return-34%1

MID & LONG-TERM▾SCORE

% of 52-week high43%1

1-year return-49%1

3-year return+155%9

5-year return+137%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +155% over three years and +137% over five, ahead of 80% of the market.

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

It's down 49% over the past year, now 57% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-10%) and so far this year (-34%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on 3SBio Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

15303SBio

Revenue FY25$2.5B

GROWTH RATING↗

WEAK28 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+36%10

Revenue, next 1Y-45%1

Revenue, next 3Y, CAGR-15%1

Revenue, next 5Y, CAGR+7%6

EARNINGS FORECAST▾SCORE

EPS growth, FY26E-71%1

EPS growth, FY27E+26%8

EPS growth, FY28E+19%8

GROWTH ASSESSMENT

STRENGTHS

Revenue grew 36%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

WATCH

Over five years revenue is set to grow 7%/yr, ahead of 50% of companies worldwide.6/10

Earnings are set to grow faster than sales (EPS about 19%/yr vs revenue -15%/yr), so margins should widen. One year dips: EPS falls 71% next year.

WEAKNESSES

Growth is the weak spot here, trailing 72% of companies worldwide.

Revenue is set to shrink 15%/yr over the next 3 years, behind most of the market.3/10

Revenue grew 36%/yr over the last 3 years, but it is set to shrink 15%/yr from here.

BOTTOM LINE

Steady Grower

Growth is a weak point here: a business heading into decline. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

15303SBio

Total return Current108%

Price return Current97.0%

MOMENTUM RATING↗

WEAK28 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-5%5

3-month return-10%3

YTD return-34%1

MID & LONG-TERM▾SCORE

% of 52-week high43%1

1-year return-49%1

3-year return+155%9

5-year return+137%8

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +155% over three years and +137% over five, ahead of 80% of the market.

WATCH

Returns sit at the market level over the past month (-5%).

WEAKNESSES

It's down 49% over the past year, now 57% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-10%) and so far this year (-34%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on 3SBio Inc.. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community